aTYR PHARMA (ATYR) Income from Non-Controlling Interests (2020 - 2026)
aTYR PHARMA's (ATYR) quarterly Income from Non-Controlling Interests came in at -$1000.0 in Q1 2026, little changed YoY from -$1000.0 in Q1 2025, and little changed on a QoQ basis from -$1000.0 in Q4 2025.
aTYR PHARMA (ATYR) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has 7 years of Income from Non-Controlling Interests data on file, last reported at -$1000.0 in Q1 2026.
- Quarterly Income from Non-Controlling Interests changed 0.0% year-over-year to -$1000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5000.0 (down 25.0% YoY) and the FY2025 annual result came in at -$5000.0, down 600.0% from the prior year.
- Income from Non-Controlling Interests held at -$1000.0 in Q1 2026, from -$1000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $4000.0 in Q1 2024 to a low of -$4000.0 in Q2 2023.
- A 5-year average of -$1125.0 and a median of -$1000.0 in 2022 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2023 — Income from Non-Controlling Interests sank 300.0% — and 2024, when it soared 500.0%.
- Tracing ATYR's Income from Non-Controlling Interests over 5 years: stood at -$2000.0 in 2022, then jumped by 50.0% to -$1000.0 in 2023, then changed by 0.0% to -$1000.0 in 2024, then changed by 0.0% to -$1000.0 in 2025, then changed by 0.0% to -$1000.0 in 2026.
- The last three Income from Non-Controlling Interests figures came in at -$1000.0 (Q1 2026), -$1000.0 (Q4 2025), and -$2000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | aTYR PHARMA | 49.54 Mn | -7.87 Mn | - | -1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,000.00 |
| Mar 31, 2026 | -1,000.00 |
| Dec 31, 2025 | -1,000.00 |
| Sep 30, 2025 | -2,000.00 |
| Jun 30, 2025 | -1,000.00 |
| Mar 31, 2025 | -1,000.00 |
| Dec 31, 2024 | -1,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Mar 31, 2024 | 4,000.00 |
| Dec 31, 2023 | -1,000.00 |
| Sep 30, 2023 | -2,000.00 |
| Jun 30, 2023 | -4,000.00 |
| Mar 31, 2023 | -1,000.00 |
| Dec 31, 2022 | -2,000.00 |
| Sep 30, 2022 | -1,000.00 |
| Jun 30, 2022 | -1,000.00 |
| Mar 31, 2022 | -1,000.00 |
| Dec 31, 2021 | -2,000.00 |
| Sep 30, 2021 | -2,000.00 |
| Jun 30, 2021 | -1,000.00 |